Search

everythinglearnresearchcommunity

for

Search:↓

Using finasteride or dutasteride does not increase the risk of male breast cancer.

Finasteride reduces prostate cancer risk but may increase high-grade tumors and has side effects; biopsy methods have similar outcomes; psychosocial factors affect sexual recovery post-surgery.

The authors suggest that 5-α-reductase inhibitors, like dutasteride, are effective in treating frontal fibrosing alopecia and should be the first-line treatment, with other options for severe cases. They also recommend further research on Janus kinase inhibitors.

The review suggests there's no agreed treatment for Frontal Fibrosing Alopecia, but hydroxychloroquine and 5a-reductase inhibitors are most effective. New treatments like platelet-rich plasma and LED light could help if standard treatments fail.

Some treatments can stabilize Frontal Fibrosing Alopecia, but more research is needed to find effective treatments, and hair transplants often fail.

5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.

Canadian lawsuits involving 5-alpha-reductase inhibitors are related to persistent erectile dysfunction side effects, with no judgments against companies yet.

5-alpha-reductase inhibitors lower PSA density but higher PSA density indicates disease progression.

Dutasteride and finasteride can help increase hair growth gene expression but need further improvement.

5-Alpha-Reductase inhibitors shorten COVID-19 recovery time in men.

Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.

Finasteride and dutasteride do not significantly change beard thickness in men.

Taking 5-alpha reductase inhibitors does not increase the risk of breast cancer in men.

5-alpha-reductase inhibitors may reduce COVID-19 symptoms in bald males.

5α-Reductase inhibitors can negatively affect male sexual function and, in some cases, significantly reduce sperm count, but these effects may be reversible.

5-alpha reductase inhibitors can cause sexual, neurologic, endocrine, and cardiovascular side effects, but these are rare and usually stop after ending treatment.

Men taking 5α-reductase inhibitors for enlarged prostate have a higher chance of experiencing reduced sexual desire and erectile dysfunction.

Urologic diseases and treatments in older men can negatively affect fertility, and doctors should talk to patients about this.

5-alpha reductase inhibitors slightly increase the risk of sexual and mood side effects, and breast growth in men.

5-alpha-reductase inhibitors may cause a low incidence of erectile dysfunction that decreases over time.

5-alpha reductase inhibitors can cause sexual side effects like erectile dysfunction and reduced sexual desire, sometimes lasting after stopping the drug.

5-Alpha Reductase Inhibitors are effective for male hair loss and some skin conditions, but their effectiveness in women and safety concerns require careful use.

5-alpha reductase inhibitors slightly reduce urinary symptoms and may lower surgery and acute retention risks in men.

5-alpha reductase inhibitors may help protect the brain and gut in Parkinson's disease.

PrEP doesn't increase STI risk in high-risk men, anti-androgen drugs may lower ICU admission for male COVID-19 patients, a 3-point injection is better for crow's feet, and the 'Geriatric-8' tool could help assess frailty in older skin cancer patients.

Medicines for enlarged prostate may raise the risk of breast growth and tenderness but not breast cancer.

Using finasteride or dutasteride may cause long-lasting erectile dysfunction.

Lower finasteride doses had more side effects; dutasteride caused back pain; more research needed on post-finasteride syndrome.

The document concludes that the risk of sexual side effects from 5-alpha-reductase inhibitors is low and often temporary, but more research is needed on potential permanent effects.

Men taking dutasteride may have a higher risk of age-related macular degeneration.